Protease-Activated Receptor-2 as a Proteolytic Rheostat in Colorectal and Pancreatic Cancer: From Mechanism to Biomarker-Guided Therapy
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27177526 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Hodasadat Tabatabaei Yeganeh und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Health, Dubai 505055, United Arab Emirates. Hauptthemen laut MEDLINE: Receptor, PAR-2, Pancreatic Neoplasms, Colorectal Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 194 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mohammed bin Rashid University of Medicine and Health Sciences.
Abstract (Originalsprache)
Protease-activated receptor-2 (PAR-2; encoded by F2RL1) is emerging as a context-dependent driver of gastrointestinal cancer. Activated by irreversible N-terminal cleavage, its signalling output is not fixed but is calibrated by the identity and source of the activating protease, the receptor cleavage state, cellular context and biased coupling to G-protein αq (Gαq), G-protein α12/13 (Gα12/13) and β-arrestin. PAR-2 is best understood not as a simple inflammatory receptor but as a proteolytic rheostat that converts diverse coagulation, inflammatory, microbial and stromal protease inputs into distinct oncogenic programmes. Colorectal cancer and pancreatic ductal adenocarcinoma provide complementary models: in colorectal cancer, PAR-2 links mucosal inflammation and coagulation to proliferation, metastatic competence and resistance to epidermal growth factor receptor (EGFR)-targeted therapy, whereas in pancreatic cancer, it is embedded in a tissue-factor-rich desmoplastic microenvironment that promotes invasion, immune exclusion and chemoresistance. Therapeutic strategies suggested by this framework include direct and biased PAR-2 modulators, upstream protease and factor Xa (FXa) inhibition, statin repurposing and activated-fragment biomarkers such as the PAR-2 activation neoepitope (PRO-PAR2). These strategies must be applied under biomarker guidance, since PAR-2 blockade may benefit inflammation-dominant tumours yet prove counterproductive where PAR-2 sustains antitumour immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Health, Dubai 505055, United Arab Emirates.
ORCID-Profile: Hodasadat Tabatabaei Yeganeh, Malak Sellat, Zayd Anis, Reine Chiri, Shloka Gambhir, Yajnavalka Banerjee
Förderung
- Mohammed bin Rashid University of Medicine and Health Sciences
Zitieren
APA
Yeganeh, H. T., Sellat, M., Anis, Z., Chiri, R., Patnaik, R., Gambhir, S., & Banerjee, Y. (2026). Protease-Activated Receptor-2 as a Proteolytic Rheostat in Colorectal and Pancreatic Cancer: From Mechanism to Biomarker-Guided Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27177526
Vancouver
Yeganeh HT, Sellat M, Anis Z, Chiri R, Patnaik R, Gambhir S, et al. Protease-Activated Receptor-2 as a Proteolytic Rheostat in Colorectal and Pancreatic Cancer: From Mechanism to Biomarker-Guided Therapy. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27177526
BibTeX
@article{Yeganeh2026,
author = {Yeganeh, Hodasadat Tabatabaei and Sellat, Malak and Anis, Zayd and Chiri, Reine and Patnaik, Rajashree and Gambhir, Shloka and Banerjee, Yajnavalka},
title = {Protease-Activated Receptor-2 as a Proteolytic Rheostat in Colorectal and Pancreatic Cancer: From Mechanism to Biomarker-Guided Therapy},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27177526}
}
EUVIMED